The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity

Drug Discovery Today

Volumn 12, Issue 23-24, 2007, Pages 1076-1082

  Fagerholm, Urban ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; ANTIVIRUS AGENT; CAFFEINE; CENTRAL NERVOUS SYSTEM AGENTS; CYCLOSPORIN A; FLUOXETINE; HYDROCORTISONE; LOPERAMIDE; MANNITOL; METHOTREXATE; NICOTINE; PHENAZONE; PROPRANOLOL DERIVATIVE; QUINIDINE; THEOBROMINE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; ZALCITABINE;

BLOOD BRAIN BARRIER; BRAIN REGION; CELL LINE; DRUG ABSORPTION; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW;

EID: 36549055143     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.10.005     Document Type: Review

References (62)

1. Su Y., and Sinko P.J. Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it?. Expert Opin. Drug Deliv. 3 (2006) 419-435
2. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Intervent. 3 (2003) 90-105
3. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
4. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 1/2 (2007) 54-61
5. Fischer H., et al. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165 (1998) 201-211
6. Kelder J., et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16 (1999) 1514-1519
7. van de Waterbeemd H., et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and h-bonding descriptors. J. Drug Targ. 6 (1998) 151-165
8. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8 (2003) 927-933
9. Kalvass J.C., et al. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration rations to in vivo P-glycoprotein efflux ratios. Drug Met. Disp. 35 (2007) 660-666
10. Liu X., et al. use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313 (2005) 1254-1262
11. Gervasini G., et al. Potential role of the cerebral cytochrome P450 in clinical pharmacokinetics. Clin. Pharmacokinet. 43 (2004) 693-706
12. Willmann S., et al. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47 (2004) 4022-4031
13. Lundquist S., et al. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between in vitro cell models. Pharm. Res. 19 (2002) 976-981
14. Goodwin J.T., and Clark D.E. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind". J. Pharmacol. Exp. Ther. 315 (2005) 477-483
15. Lindstedt S.L., and Schaeffer P.J. Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Anim. 36 (2002) 1-19
16. Davis S.S. Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gammascintigraphy. S.T.P Pharma 2 (1986) 1015-1022
17. Leggett R.W., and Williams L.R. A proposed blood circulation model for reference man. Health Phys. 69 (1995) 187-201
18. Hitchcock S.A., and Pennington L.D. Structure-brain exposure relationships. J. Med. Chem. 49 (2006) 7559-7583
19. Chiou W.L., and Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rat. Pharm. Res. 15 (1998) 1792-1795
20. Sobue K., et al. Aquaporin water channels in the brain and molecular mechanisms of brain edema. Jpn. J. Clin. Med. 64 (2006) 1181-1189
21. Fagerholm U., et al. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13 (1996) 1336-1342
22. Leggett R.W., and Williams L.R. Suggested reference values for regional blood volumes in humans. Health Phys. 60 (1991) 139-154
23. Karlsson J., and Artursson P. A new diffusion chamber system for the determination of drug permeability coefficients across the human intestinal epithelium that are independent on the unstirred water layer. Biochim. Biophys. Acta 1111 (1992) 204-210
24. Kawakami J., et al. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J. Pharmacokin. Biopharm. 22 (1994) 207-227
25. Mellick G.D., and Roberts M.S. The disposition of aspirin and salicylic acid in the isolated perfused rat liver: the effect of normal and retrograde flow on availability and mean transit time. J. Pharmacy Pharmacol. 48 (1996) 738-743
26. Chiou W.L., and Beuhler P.W. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. 19 (2002) 868-874
27. Garberg P., et al. In vitro models for the blood-brain barrier. Toxicol. In Vitro 19 (2005) 299-334
28. Alpini G., et al. Water and nonelectrolyte permeability of isolated rat hepatocytes. Am. J. Physiol. 251 (1986) C872-C882
29. Miyauchi S., et al. Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm. Res. 10 (1993) 434-440
30. Irvine J.D., et al. MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88 (1999) 29-33
31. Matsson P., et al. Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48 (2005) 604-613
32. Lennernäs H., et al. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharmaceut. 127 (1996) 103-107
33. Fagerholm U., and Lennernäs H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3 (1995) 247-253
34. Fagerholm U., et al. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol. Scand. 165 (1999) 315-324
35. Begley D.J. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48 (1996) 136-146
36. Abbruscato T.J., et al. Blood-brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: Comparison with morphine. J. Pharmacol. Exp. Ther. 280 (1997) 402-409
37. Lennernäs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 49 (1997) 627-638
38. Syvänen S., et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. NeuroImage 32 (2006) 1134-1141
39. van Asperen J., et al. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86 (1997) 881-884
40. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88 (1999) 815-821
41. Tamai I., and Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 11 (2000) 1371-1388
42. Berezowski V., et al. Transport of drug cocktails through an in vitro blood-brain barrier: is it a good strategy for increasing the throughput of the discovery pipeline?. Pharm. Res. 21 (2004) 756-760
43. Borg N., and Ståhle L. Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2′,3′-dideoxycytidine) and BEA0005 (2′,3′-dideoxy-3′-hydroxymethylcytidine) in rats, studied by microdialysis. Antimicrob. Agents Chemother. 48 (1998) 2174-2177
44. 2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J. Pharmacol. Exp. Ther. 281 (1997) 817-825
45. Kakee A., et al. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277 (1996) 1550-1559
46. Dehouck M.-P., et al. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake if the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res. 955 (2002) 229-235
47. McLennan I.S., et al. Transport of transforming growth factor-β2 across the blood-brain barrier. Neuropharmacology 48 (2005) 274-282
48. de Lange E.C.M., and Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Clin. Pharmacokinet. 41 (2002) 691-703
49. Le Couteur D.G., et al. The hepatic sinusoid in aging and cirrhosis. Effects on hepatic substrate disposition and drug clearance. Clin. Pharmacokin. 44 (2005) 187-200
50. Koziara J.M., et al. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20 (2003) 1772-1778
51. Costantino L., et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Rel. 108 (2005) 84-96
52. Diamond M.S., and Klein R.S. West Nile virus: crossing the blood-brain barrier. Nat. Med. 10 (2004) 1294-1295
53. Banks W.A., et al. Permeability of the blood-brain barrier to HIV-1 Tat. Exp. Neurol. 193 (2005) 218-227
54. Doran K.S., et al. Blood-brain barrier invasion by group B streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J. Clin. Invest. 115 (2005) 2499-2507
55. Winkler D.A., and Burden F.R. Modelling blood-brain barrier partitioning using Bayesisn neural nets. J. Mol. Graph. Model. 22 (2004) 499-505
56. Fagerholm U. Prediction of human pharmacokinetics - evaluation of methods for prediction of volume of distribution. J. Pharm. Pharmacol. 59 (2007) 1181-1190
57. Smith D.A., et al. In: Smith D.A., van de Waterbeemd H., and Walker D.K. (Eds). Pharmacokinetics and Metabolism in Drug Design (Chapter 4) (2001), Wiley-VCH, New York, Chichester
58. Boström E., et al. In vivo blood-brain barrier transport of oxycodone in the rat: indications of active influx and implications for pharmacokinetics/pharmacodynamics. Drug Met. Disp. 34 (2006) 1624-1631
59. Hansen D.K., et al. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J. Pharmaceut. Biomed. Anal. 27 (2002) 945-958
60. Garg P., and Verma J. In silico prediction of blood brain barrier permeability: an artifical neural network model. J. Chem. Inf. Model. 46 (2006) 289-297
61. Sandström R., et al. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15 (1998) 856-862
62. Sadeque A.J.M., et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68 (2000) 231-237